FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760872777> ?p ?o ?g. }

• W2760872777 abstract "Abstract Background: The phase 3 B-LONG and Kids B-LONG studies demonstrated low annualized bleeding rates (ABRs) with rFIXFc prophylaxis in subjects with severe hemophilia B. Compared with prestudy FIX treatment, rFIXFc prophylaxis reduced weekly factor consumption and infusion frequency. Aims: To evaluate the effect of rFIXFc on subjects' physical activity across age groups using a subject-reported assessment and to examine ABRs with respect to change in physical activity and prestudy treatment regimen (prophylaxis or episodic) in B-LONG and Kids B-LONG. Methods: Previously treated males with severe haemophilia B (≤ 2 IU/dL endogenous FIX activity) were eligible for B-LONG (≥ 12 years of age) and Kids B-LONG (<12 years of age). Subjects in B-LONG were enrolled into 1 of 4 treatment arms: Arm 1, weekly prophylaxis; Arm 2, individualized interval prophylaxis; Arm 3, episodic treatment; or Arm 4, perioperative management (not included in this analysis). All subjects in Kids B-LONG started on weekly rFIXFc prophylaxis. There were no restrictions on physical activity in either study. Physical activity assessments were conducted at Weeks 4, 16, 26, 39, and 52 (B-LONG) and Weeks 3, 12, 24, 36, and 50 (Kids B-LONG). At each visit after their first rFIXFc dose, subjects were asked to report activity levels relative to their prior study visit as: more (or more intensive), fewer (or less intensive), or about the same amount of physical activities. To summarize each subject's change in physical activity during the study compared with baseline, subjects were classified into one of 4 groups: more, the same, less, or undetermined. Within each treatment group, prestudy and on-study ABRs were analyzed according to change in physical activity category and prestudy regimen. Analyses included all subjects who received ≥ 1 dose of rFIXFc during the efficacy period and who completed ≥ 1 physical activity assessment. Results: This analysis included 112 subjects from B-LONG and 30 subjects from Kids B-LONG. The majority of subjects in both studies reported more or the same amount of physical activity during the study; few subjects reported less physical activity. Percent of subjects with changes in physical activity levels (more, same, less, undetermined) in B-LONG were: Arm 1 (n = 60), 35%, 42%, 7%, 17%; Arm 2 (n = 25), 48%, 28%, 16%, 8%; Arm 3 (n = 27), 30%, 26%, 15%, 30%; and in Kids B-LONG (n = 30) were: 57%, 20%, 10%, 13%, respectively. Similar physical activity results were observed in subjects with and without target joints at baseline. Median on-study ABRs with rFIXFc prophylaxis were low in B-LONG and Kids B-LONG for all categories of change in physical activity; for subjects on prestudy prophylaxis who reported more or similar physical activity during B-LONG/Kids B-LONG, median ABRs with rFIXFc were similar or lower compared with prestudy ABR (Table). Summary/Conclusion: The majority of subjects in B-LONG (71%) and Kids B-LONG (77%) maintained or increased physical activity levels during the study. ABRs were low in both studies, regardless of change in physical activity. These results suggest that people with severe hemophilia B across age groups may maintain or increase their physical activity levels with rFIXFc while also maintaining low bleeding rates with reduced infusion frequency. Table 1. Prestudy and On-study Median (IQR) ABR by Physical Activity Level in B-LONG and Kids B-LONG Parent study: B-LONG Kids B-LONG On-study rFIXFc prophylaxis: Arm 1 (weekly) Arm 2 (individualized interval) Weekly Prestudy FIX regimen: Prophylaxis (n = 30) Episodic (n = 28) Prophylaxis (n = 13) Episodic (n = 13) Prophylaxis (n = 30) Median (IQR) ABR by physical activity category More n = 6 n = 11 n = 5 n = 5 n = 17 Prestudy 6.00 (1.00, 15.00) 14.00(11.00, 28.00) 1.00(0, 1.00) 25.00(22.00, 25.00) 2.00(0, 3.00) On-study 4.76 (3.09, 5.62) 3.13(1.14, 4.34) 0(0, 0.72) 2.19(1.66, 2.61) 2.09(0, 3.13) Same n = 15 n = 10 n = 2 n = 5 n = 6 Prestudy 1.00(1.00, 6.00) 26.00(20.00, 40.00) 4.00(1.00, 7.00) 33.00(27.00, 39.00) 2.50(0, 3.00) On-study 1.13(0, 2.30) 2.62(0.99, 5.23) 1.15(0, 2.30) 1.09(0, 4.43) 0.53(0, 2.90) Less n = 3 n = 0 n = 2 n = 1 n = 3 Prestudy 0(0,0) -- 3.00(2.00, 4.00) 22.00 5.00(2.00, 6.00) On-study 0(0,0) -- 3.78(0, 7.56) 0 1.85(1.06, 5.43) Undetermined n = 4 n = 5 n = 1 n = 1 n = 4 Prestudy 4.50(2.50, 8.00) 25.00(20.00, 40.00) 4.00 12.00 7.00(3.50, 13.00) On-study 3.76(1.76, 5.35) 1.04(0, 1.16) 0 3.12 2.21(1.09, 3.92) ABR, annualized bleeding rate; IQR, interquartile range. Disclosures Kulkarni: Baxter: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees; Kedrion: Membership on an entity's Board of Directors or advisory committees; BPL: Membership on an entity's Board of Directors or advisory committees; Biogen: Research Funding, Speakers Bureau. Shapiro:Baxalta, Novo Nordisk, Biogen, ProMetic Life Sciences, and Kedrion Biopharma: Consultancy; Biogen: Speakers Bureau; Bayer Healthcare, Baxalta, Biogen, CSL Behring, Daiichi Sankyo, Kedrion Biopharma, Octapharma, OPKO, ProMetic Life Sciences, PTC Therapeutics, and Selexys: Research Funding; Baxalta, Novo Nordisk, Biogen,: Membership on an entity's Board of Directors or advisory committees. Windyga:Baxalta, Novo Nordisk, and Biogen: Research Funding; Baxalta, Novo Nordisk, Sanofi, CSL Behring, Bayer, and Pfizer: Honoraria; Baxalta, Novo Nordisk, Sanofi, Biogen, CSL Behring, Bayer, and Pfizer: Membership on an entity's Board of Directors or advisory committees. Ragni:SPARK: Research Funding; Alnylam: Research Funding; Bristol Myers Squibb: Research Funding; Biomarin: Research Funding; Shire: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Genentech Roche: Research Funding; Pfizer: Research Funding; CSL Behring: Research Funding; Vascular Medicine Institute: Research Funding; Dimension: Research Funding; Baxalta: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Biogen: Research Funding; Tacere Benitec: Membership on an entity's Board of Directors or advisory committees. Pasi:Octapharma: Research Funding; Biogen, Octapharma, Genzyme, and Pfizer: Consultancy, Honoraria. Ozelo:Baxter: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Biogen: Research Funding; Novo Nordisk: Research Funding, Speakers Bureau. Tsao:Biogen: Employment, Equity Ownership. Mei:Biogen: Employment, Equity Ownership." @default.
• W2760872777 created "2017-10-20" @default.
• W2760872777 creator A5001640507 @default.
• W2760872777 creator A5006881585 @default.
• W2760872777 creator A5018946153 @default.
• W2760872777 creator A5027136982 @default.
• W2760872777 creator A5036747329 @default.
• W2760872777 creator A5038597185 @default.
• W2760872777 creator A5043857390 @default.
• W2760872777 creator A5072032667 @default.
• W2760872777 creator A5073241613 @default.
• W2760872777 date "2015-12-03" @default.
• W2760872777 modified "2023-09-27" @default.
• W2760872777 title "Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies" @default.
• W2760872777 doi "https://doi.org/10.1182/blood.v126.23.2307.2307" @default.
• W2760872777 hasPublicationYear "2015" @default.
• W2760872777 type Work @default.
• W2760872777 sameAs 2760872777 @default.
• W2760872777 citedByCount "1" @default.
• W2760872777 countsByYear W27608727772017 @default.
• W2760872777 crossrefType "journal-article" @default.
• W2760872777 hasAuthorship W2760872777A5001640507 @default.
• W2760872777 hasAuthorship W2760872777A5006881585 @default.
• W2760872777 hasAuthorship W2760872777A5018946153 @default.
• W2760872777 hasAuthorship W2760872777A5027136982 @default.
• W2760872777 hasAuthorship W2760872777A5036747329 @default.
• W2760872777 hasAuthorship W2760872777A5038597185 @default.
• W2760872777 hasAuthorship W2760872777A5043857390 @default.
• W2760872777 hasAuthorship W2760872777A5072032667 @default.
• W2760872777 hasAuthorship W2760872777A5073241613 @default.
• W2760872777 hasConcept C104317684 @default.
• W2760872777 hasConcept C126322002 @default.
• W2760872777 hasConcept C185592680 @default.
• W2760872777 hasConcept C40767141 @default.
• W2760872777 hasConcept C55493867 @default.
• W2760872777 hasConcept C71924100 @default.
• W2760872777 hasConcept C90924648 @default.
• W2760872777 hasConceptScore W2760872777C104317684 @default.
• W2760872777 hasConceptScore W2760872777C126322002 @default.
• W2760872777 hasConceptScore W2760872777C185592680 @default.
• W2760872777 hasConceptScore W2760872777C40767141 @default.
• W2760872777 hasConceptScore W2760872777C55493867 @default.
• W2760872777 hasConceptScore W2760872777C71924100 @default.
• W2760872777 hasConceptScore W2760872777C90924648 @default.
• W2760872777 hasLocation W27608727771 @default.
• W2760872777 hasOpenAccess W2760872777 @default.
• W2760872777 hasPrimaryLocation W27608727771 @default.
• W2760872777 hasRelatedWork W185071620 @default.
• W2760872777 hasRelatedWork W2559117881 @default.
• W2760872777 hasRelatedWork W2559145035 @default.
• W2760872777 hasRelatedWork W2603207226 @default.
• W2760872777 hasRelatedWork W2612853764 @default.
• W2760872777 hasRelatedWork W266507365 @default.
• W2760872777 hasRelatedWork W2795172151 @default.
• W2760872777 hasRelatedWork W2908247797 @default.
• W2760872777 hasRelatedWork W2908370917 @default.
• W2760872777 hasRelatedWork W2912457465 @default.
• W2760872777 hasRelatedWork W2920789639 @default.
• W2760872777 hasRelatedWork W2979624149 @default.
• W2760872777 hasRelatedWork W2979686089 @default.
• W2760872777 hasRelatedWork W2983734708 @default.
• W2760872777 hasRelatedWork W2988072482 @default.
• W2760872777 hasRelatedWork W2990683497 @default.
• W2760872777 hasRelatedWork W3094682879 @default.
• W2760872777 hasRelatedWork W3095307614 @default.
• W2760872777 hasRelatedWork W3097357948 @default.
• W2760872777 hasRelatedWork W3129043194 @default.
• W2760872777 isParatext "false" @default.
• W2760872777 isRetracted "false" @default.
• W2760872777 magId "2760872777" @default.
• W2760872777 workType "article" @default.